160 related articles for article (PubMed ID: 16322279)
1. Liposomal, nanoparticle, and conjugated formulations of anticancer agents.
Zamboni WC
Clin Cancer Res; 2005 Dec; 11(23):8230-4. PubMed ID: 16322279
[No Abstract] [Full Text] [Related]
2. Cancer therapy with liposomal formulations of anticancer drugs.
Massing U
Int J Clin Pharmacol Ther; 1997 Feb; 35(2):87-90. PubMed ID: 9147717
[No Abstract] [Full Text] [Related]
3. Liposomal nanomedicines as anticancer therapeutics: beyond targeting tumor cells.
Schiffelers RM; Storm G
Int J Pharm; 2008 Dec; 364(2):258-64. PubMed ID: 18773947
[TBL] [Abstract][Full Text] [Related]
4. Concept and clinical evaluation of carrier-mediated anticancer agents.
Zamboni WC
Oncologist; 2008 Mar; 13(3):248-60. PubMed ID: 18378535
[TBL] [Abstract][Full Text] [Related]
5. Drug delivery in cancer using liposomes.
Dass CR
Methods Mol Biol; 2008; 437():177-82. PubMed ID: 18369969
[TBL] [Abstract][Full Text] [Related]
6. Liposomal nanomedicines.
Fenske DB; Cullis PR
Expert Opin Drug Deliv; 2008 Jan; 5(1):25-44. PubMed ID: 18095927
[TBL] [Abstract][Full Text] [Related]
7. A liposomal delivery vehicle for the anticancer agent gossypol.
Zhai G; Wu J; Zhao X; Yu B; Li H; Lu Y; Ye W; Lin YC; Lee RJ
Anticancer Res; 2008; 28(5A):2801-5. PubMed ID: 19035313
[TBL] [Abstract][Full Text] [Related]
8. Systemic anti-tumor activity of liposomal glucocorticoids.
Park K
J Control Release; 2011 Apr; 151(1):1. PubMed ID: 21440020
[No Abstract] [Full Text] [Related]
9. Nano- or submicron-sized liposomes as carriers for drug delivery.
Fang JY
Chang Gung Med J; 2006; 29(4):358-62. PubMed ID: 17051832
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticle therapeutics: an emerging treatment modality for cancer.
Davis ME; Chen ZG; Shin DM
Nat Rev Drug Discov; 2008 Sep; 7(9):771-82. PubMed ID: 18758474
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of doxorubicin encapsulated in hexadecylphosphocholine (HePC) liposomes against human xenografts on Scid mice.
Papagiannaros A; Hatziantoniou S; Lelong-Rebel IH; Papaioannou GT; Dimas K; Demetzos C
In Vivo; 2006; 20(1):129-35. PubMed ID: 16433041
[TBL] [Abstract][Full Text] [Related]
12. Physical mechanisms and methods employed in drug delivery to tumors.
Besić E
Acta Pharm; 2007 Sep; 57(3):249-68. PubMed ID: 17878107
[TBL] [Abstract][Full Text] [Related]
13. Effect of liposome encapsulation of tea catechins on their accumulation in basal cell carcinomas.
Fang JY; Lee WR; Shen SC; Huang YL
J Dermatol Sci; 2006 May; 42(2):101-9. PubMed ID: 16423506
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel prodrugs: toward smarter delivery of anticancer agents.
Skwarczynski M; Hayashi Y; Kiso Y
J Med Chem; 2006 Dec; 49(25):7253-69. PubMed ID: 17149855
[No Abstract] [Full Text] [Related]
15. pH-sensitive liposomes--principle and application in cancer therapy.
Karanth H; Murthy RS
J Pharm Pharmacol; 2007 Apr; 59(4):469-83. PubMed ID: 17430630
[TBL] [Abstract][Full Text] [Related]
16. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA; Owais M
J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
[TBL] [Abstract][Full Text] [Related]
17. Elimination of liposomes by different separation principles used in low-density lipoprotein apheresis.
Pütz G; Eckes J; Schmah O; Winkler K; Wieland H
Ther Apher Dial; 2008 Feb; 12(1):2-12. PubMed ID: 18257806
[TBL] [Abstract][Full Text] [Related]
18. Role of anthracyclines in the era of targeted therapy.
Cortés-Funes H; Coronado C
Cardiovasc Toxicol; 2007; 7(2):56-60. PubMed ID: 17652804
[TBL] [Abstract][Full Text] [Related]
19. Higher liposomal membrane fluidity enhances the in vitro antitumor activity of folate-targeted liposomal mitoxantrone.
Kawano K; Onose E; Hattori Y; Maitani Y
Mol Pharm; 2009; 6(1):98-104. PubMed ID: 19072653
[TBL] [Abstract][Full Text] [Related]
20. [New trends in anticancer chemotherapy].
Mathé G
Rev Fr Etud Clin Biol; 1967 May; 12(5):425-32. PubMed ID: 5614799
[No Abstract] [Full Text] [Related]
[Next] [New Search]
